Integer Holdings Corp (ITGR)

$117.83

-0.69

(-0.58%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Integer Holdings Corp

  • Increasing Revenue

    Revenue is up for the last 6 quarters, 342.68M → 413.15M (in $), with an average increase of 3.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 27.25M → 26.35M (in $), with an average decrease of 3.3% per quarter

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 66.1% return, outperforming this stock by 38.7%

Performance

  • $117.56
    $119.45
    $117.83
    downward going graph

    0.23%

    Downside

    Day's Volatility :1.58%

    Upside

    1.36%

    downward going graph
  • $69.40
    $121.53
    $117.83
    downward going graph

    41.1%

    Downside

    52 Weeks Volatility :42.89%

    Upside

    3.04%

    downward going graph

Returns

PeriodInteger Holdings CorpSector (Health Care)Index (Russel 2000)
3 Months
14.9%
-0.7%
0.0%
6 Months
59.02%
6.6%
0.0%
1 Year
48.15%
3.7%
-1.5%
3 Years
27.39%
14.0%
-21.8%

Highlights

Market Capitalization
4.0B
Book Value
$45.58
Earnings Per Share (EPS)
2.68
PE Ratio
44.52
PEG Ratio
1.63
Wall Street Target Price
124.86
Profit Margin
5.68%
Operating Margin TTM
12.57%
Return On Assets TTM
3.99%
Return On Equity TTM
6.17%
Revenue TTM
1.6B
Revenue Per Share TTM
47.92
Quarterly Revenue Growth YOY
10.9%
Gross Profit TTM
359.0M
EBITDA
282.1M
Diluted Eps TTM
2.68
Quarterly Earnings Growth YOY
0.44
EPS Estimate Current Year
5.31
EPS Estimate Next Year
6.04
EPS Estimate Current Quarter
1.33
EPS Estimate Next Quarter
1.17

Analyst Recommendation

Buy
    69%Buy
    30%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Integer Holdings Corp(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
10
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 5.97%

Current $117.83
Target $124.86

Company Financials

FY18Y/Y Change
Revenue
1.2B
↓ 16.89%
Net Income
168.0M
↑ 151.9%
Net Profit Margin
13.82%
↑ 9.26%
FY19Y/Y Change
Revenue
1.3B
↑ 3.55%
Net Income
96.3M
↓ 42.64%
Net Profit Margin
7.66%
↓ 6.16%
FY20Y/Y Change
Revenue
1.1B
↓ 14.68%
Net Income
77.3M
↓ 19.8%
Net Profit Margin
7.2%
↓ 0.46%
FY21Y/Y Change
Revenue
1.2B
↑ 13.75%
Net Income
96.8M
↑ 25.3%
Net Profit Margin
7.93%
↑ 0.73%
FY22Y/Y Change
Revenue
1.4B
↑ 12.7%
Net Income
66.4M
↓ 31.43%
Net Profit Margin
4.82%
↓ 3.11%
FY23Y/Y Change
Revenue
1.6B
↑ 16.03%
Net Income
90.7M
↑ 36.57%
Net Profit Margin
5.68%
↑ 0.86%
Q3 FY22Q/Q Change
Revenue
342.7M
↓ 2.11%
Net Income
16.1M
↓ 22.94%
Net Profit Margin
4.69%
↓ 1.26%
Q4 FY22Q/Q Change
Revenue
372.4M
↑ 8.68%
Net Income
18.1M
↑ 12.83%
Net Profit Margin
4.86%
↑ 0.17%
Q1 FY23Q/Q Change
Revenue
378.8M
↑ 1.71%
Net Income
13.1M
↓ 27.89%
Net Profit Margin
3.45%
↓ 1.41%
Q2 FY23Q/Q Change
Revenue
400.0M
↑ 5.61%
Net Income
24.0M
↑ 83.47%
Net Profit Margin
5.99%
↑ 2.54%
Q3 FY23Q/Q Change
Revenue
404.7M
↑ 1.16%
Net Income
27.3M
↑ 13.71%
Net Profit Margin
6.74%
↑ 0.75%
Q4 FY23Q/Q Change
Revenue
413.2M
↑ 2.09%
Net Income
26.4M
↓ 3.3%
Net Profit Margin
6.38%
↓ 0.36%
FY18Y/Y Change
Total Assets
2.3B
↓ 18.31%
Total Liabilities
1.3B
↓ 35.23%
FY19Y/Y Change
Total Assets
2.4B
↑ 1.14%
Total Liabilities
1.2B
↓ 5.18%
FY20Y/Y Change
Total Assets
2.4B
↑ 0.8%
Total Liabilities
1.1B
↓ 8.31%
FY21Y/Y Change
Total Assets
2.6B
↑ 8.87%
Total Liabilities
1.2B
↑ 11.51%
FY22Y/Y Change
Total Assets
2.8B
↑ 8.22%
Total Liabilities
1.4B
↑ 12.17%
FY23Y/Y Change
Total Assets
2.9B
↑ 5.31%
Total Liabilities
1.4B
↑ 2.64%
Q3 FY22Q/Q Change
Total Assets
2.7B
↓ 0.71%
Total Liabilities
1.4B
↓ 0.81%
Q4 FY22Q/Q Change
Total Assets
2.8B
↑ 2.04%
Total Liabilities
1.4B
↓ 0.47%
Q1 FY23Q/Q Change
Total Assets
2.9B
↑ 2.83%
Total Liabilities
1.5B
↑ 5.71%
Q2 FY23Q/Q Change
Total Assets
2.9B
↓ 0.42%
Total Liabilities
1.4B
↓ 2.74%
Q3 FY23Q/Q Change
Total Assets
2.8B
↓ 0.77%
Total Liabilities
1.4B
↓ 2.8%
Q4 FY23Q/Q Change
Total Assets
2.9B
↑ 3.64%
Total Liabilities
1.4B
↑ 2.71%
FY18Y/Y Change
Operating Cash Flow
167.3M
↑ 12.01%
Investing Cash Flow
536.7M
↓ 1219.56%
Financing Cash Flow
-725.1M
↑ 549.31%
FY19Y/Y Change
Operating Cash Flow
165.4M
↓ 1.16%
Investing Cash Flow
-58.9M
↓ 110.97%
Financing Cash Flow
-117.9M
↓ 83.74%
FY20Y/Y Change
Operating Cash Flow
181.3M
↑ 9.67%
Investing Cash Flow
-56.6M
↓ 3.88%
Financing Cash Flow
-88.6M
↓ 24.89%
FY21Y/Y Change
Operating Cash Flow
156.7M
↓ 13.61%
Investing Cash Flow
-271.0M
↑ 379.0%
Financing Cash Flow
82.0M
↓ 192.56%
FY22Y/Y Change
Operating Cash Flow
116.4M
↓ 25.71%
Investing Cash Flow
-200.4M
↓ 26.04%
Financing Cash Flow
92.5M
↑ 12.79%
Q3 FY22Q/Q Change
Operating Cash Flow
27.8M
↑ 47.31%
Investing Cash Flow
-20.4M
↓ 85.22%
Financing Cash Flow
-9.2M
↓ 107.88%
Q4 FY22Q/Q Change
Operating Cash Flow
51.6M
↑ 85.83%
Investing Cash Flow
-31.3M
↑ 53.25%
Financing Cash Flow
-13.9M
↑ 51.63%
Q1 FY23Q/Q Change
Operating Cash Flow
6.2M
↓ 88.01%
Investing Cash Flow
-24.7M
↓ 21.16%
Financing Cash Flow
33.1M
↓ 337.63%
Q2 FY23Q/Q Change
Operating Cash Flow
56.1M
↑ 807.32%
Investing Cash Flow
-32.7M
↑ 32.31%
Financing Cash Flow
-25.5M
↓ 177.07%
Q3 FY23Q/Q Change
Operating Cash Flow
62.3M
↑ 10.95%
Investing Cash Flow
-25.4M
↓ 22.2%
Financing Cash Flow
-43.1M
↑ 68.98%

Technicals Summary

Sell

Neutral

Buy

Integer Holdings Corp is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Integer Holdings Corp
Integer Holdings Corp
4.44%
59.02%
48.15%
27.39%
67.19%
Stryker Corporation
Stryker Corporation
-5.1%
24.37%
15.51%
30.88%
86.41%
Boston Scientific Corp.
Boston Scientific Corp.
1.07%
34.02%
31.68%
66.24%
93.56%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-6.04%
25.15%
3.43%
-1.49%
47.65%
Abbott Laboratories
Abbott Laboratories
-5.82%
10.82%
1.68%
-14.96%
43.26%
Medtronic Plc
Medtronic Plc
-5.47%
8.78%
-3.15%
-37.3%
-6.1%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Integer Holdings Corp
Integer Holdings Corp
44.52
44.52
1.63
5.31
0.06
0.04
NA
45.58
Stryker Corporation
Stryker Corporation
40.98
40.98
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
63.66
63.66
1.8
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
39.15
39.15
5.19
2.76
0.22
0.12
NA
11.06
Abbott Laboratories
Abbott Laboratories
33.4
33.4
5.99
4.59
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.16
25.16
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Integer Holdings Corp
Integer Holdings Corp
Buy
$4.0B
67.19%
44.52
5.68%
Stryker Corporation
Stryker Corporation
Buy
$128.5B
86.41%
40.98
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$100.1B
93.56%
63.66
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$54.2B
47.65%
39.15
23.36%
Abbott Laboratories
Abbott Laboratories
Buy
$189.5B
43.26%
33.4
14.27%
Medtronic Plc
Medtronic Plc
Buy
$105.2B
-6.1%
25.16
13.0%

Institutional Holdings

  • BlackRock Inc

    16.18%

  • Vanguard Group Inc

    11.38%

  • Dimensional Fund Advisors, Inc.

    6.17%

  • Franklin Resources Inc

    4.93%

  • Victory Capital Management Inc.

    4.78%

  • State Street Corporation

    3.85%

Company Information

integer holdings corporation (nyse:itgr) is a leader in advanced medical device outsourcing (mdo) and serves its customers by providing comprehensive end-to-end solutions with its unparalleled expertise in innovation and manufacturing. integer's vision is to enhance the lives of patients worldwide by being its customer's partner of choice for innovative medical technologies and services. additionally, through electrochem, an integer company, it develops custom batteries for high-end niche applications in energy, military, and environment markets. the company's medical device manufacturing brands include greatbatch™ medical and lake region medical™. additional information is available at www.integer.net.

Organization
Integer Holdings Corp
Employees
10500
CEO
Mr. Joseph W. Dziedzic
Industry
Producer Manufacturing

Discover More

FAQs